Drug Profile
Research programme: acute radiation syndrome therapy - Humanetics
Alternative Names: BIO-100; BIO-200; BIO-400Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Humanetics Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Radiation injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Radiation-injuries in USA (PO)
- 12 Jan 2006 Humanetics received $US1.25 million in funding from the US Department of Defense